Clinical trials: Breakthrough Cancer Pain
Pain, Cancer
Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer Patients
The purpose of this study is to evaluate the long-term safety and effectiveness of EN3267 in treating breakthrough pain episodes in opioid cancer patients who are using stable doses of opioid medication.
- Trial name
- NCT00263575
- Testing
- EN3267
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Breakthrough Pain, Cancer
Efficacy and Tolerability of Intranasal Fentanyl Spray for the Treatment of Breakthrough Pain in Cancer Patients Older Than 18 Years
The aim of the study was to evaluate the safety and efficacy of intranasal fentanyl spray in cancer patients over four weeks, especially during cancer-related breakthrough pain (BTP) attacks.
- Trial name
- GENISIS (NCT00994760)
- Testing
- Instanyl (Intranasal Fentanyl)
- Where
- 168 sites in Germany
- Volunteers
- 131 people
- Sponsor
- Takeda
Cancer Pain
Efficacy & Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids
Cancer patients taking regular medication for their pain often still have episodes of severe pain that 'break through' despite their background pain treatment.
- Trial name
- NCT00459277
- Testing
- Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Archimedes Development Ltd
Pain, Cancer
Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients
The purpose of this study is to evaluate the safety and tolerability of OraVescent fentanyl when used long-term to relieve breakthrough pain in opioid tolerant cancer patients.
- Trial name
- NCT00105287
- Testing
- OraVescent fentanyl (OVF)
- Where
- 26 sites in United States
- Volunteers
- 100 people
- Sponsor
- Cephalon
Cancer, Pain
Intranasal Fentanyl for the Treatment of Breakthrough Pain in Cancer Patients (FT-017-IM)
Primary Objective: To demonstrate the efficacy of intranasal fentanyl in the treatment of breakthrough pain (BTP) in cancer patients.
- Trial name
- NCT00345735
- Testing
- Fentanyl
- Where
- Denmark
- Volunteers
- 150 people
- Sponsor
- Nycomed
Cancer, Pain
A Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 (Sufentanil NanoTab) Compared to Placebo in the Treatment of Cancer Breakthrough Pain
The purpose of this research study was to evaluate ARX-F02 (Sufentanil NanoTab) versus placebo ("sugar" pill or inactive substance) in the management of breakthrough pain in cancer patients.
- Trial name
- NCT00833040
- Where
- 13 sites in United States
- Volunteers
- 34 people
- Sponsor
- Talphera, Inc
Breakthrough Cancer Pain
Instanyl® Non-Interventional Study
The aim of this study is to describe the use of Instanyl® (Intranasal fentanyl spray) in the treatment of breakthrough pain (BTP) in cancer patients by success of dose titration and distribution of dose strength.
- Trial name
- INIS (NCT01045603)
- Where
- 65 sites in Denmark, France and 5 more
- Volunteers
- 309 people
- Sponsor
- Takeda
Cancer, Pain
A Multicentre Study to Evaluate the Safety and Efficacy of AD 923 in Comparison to MSIR for the Treatment of CBP in Subjects
Purpose: The purpose of this study is to compare the efficacy and safety of AD 923 to the most widely used current treatment (MSIR) in the management of target BTP in subjects with malignancies who are taking a stable dose of…
- Trial name
- NCT00635063
- Testing
- AD 923
- Where
- United Kingdom
- Volunteers
- 150 people
- Sponsor
- Sosei